Page last updated: 2024-10-22

alfuzosin and Prostatitis

alfuzosin has been researched along with Prostatitis in 11 studies

alfuzosin: structure given in first source

Prostatitis: Infiltration of inflammatory cells into the parenchyma of PROSTATE. The subtypes are classified by their varied laboratory analysis, clinical presentation and response to treatment.

Research Excerpts

ExcerptRelevanceReference
"We conducted a multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy of alfuzosin, an alpha-adrenergic receptor blocker, in reducing symptoms in men with chronic prostatitis-chronic pelvic pain syndrome."9.13Alfuzosin and symptoms of chronic prostatitis-chronic pelvic pain syndrome. ( Alexander, RB; Anderson, RU; Berger, R; Chuai, S; Krieger, JN; Kusek, JW; Landis, JR; Liong, ML; Litwin, MS; McNaughton-Collins, M; Nadler, R; Nickel, JC; Nyberg, LM; O'Leary, M; Pontari, M; Schaeffer, AJ; Shoskes, DA; White, PC; Zeitlin, S, 2008)
"To perform a prospective, placebo-controlled study to examine the long-term efficacy of alfuzosin compared with placebo and standard therapy in patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), because alpha-blockers have been suggested for the treatment of CP/CPPS."9.10Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled, pilot study. ( Alas, P; Helström, PJ; Mehik, A; Nickel, JC; Sarpola, A, 2003)
"A double-blind, placebo-controlled study in 20 patients with 'prostatitis syndromes' and confirmed urodynamic abnormalities using the alpha 1-receptor-blocking compound alfuzosin is reported."9.07Research in 'prostatitis syndromes': the use of alfuzosin (a new alpha 1-receptor-blocking agent) in patients mainly presenting with micturition complaints of an irritative nature and confirmed urodynamic abnormalities. ( de Boo, T; de la Rosette, JJ; Debruyne, FM; Karthaus, HF; van Kerrebroeck, PE, 1992)
"We conducted a multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy of alfuzosin, an alpha-adrenergic receptor blocker, in reducing symptoms in men with chronic prostatitis-chronic pelvic pain syndrome."5.13Alfuzosin and symptoms of chronic prostatitis-chronic pelvic pain syndrome. ( Alexander, RB; Anderson, RU; Berger, R; Chuai, S; Krieger, JN; Kusek, JW; Landis, JR; Liong, ML; Litwin, MS; McNaughton-Collins, M; Nadler, R; Nickel, JC; Nyberg, LM; O'Leary, M; Pontari, M; Schaeffer, AJ; Shoskes, DA; White, PC; Zeitlin, S, 2008)
"This study shows that alfuzosin 10mg is well tolerated by young healthy subjects and may therefore be safely administered to young normotensive patients affected by distal ureteral stones and prostatitis."5.12Alfuzosin (10 mg) does not affect blood pressure in young healthy men. ( Bartoletti, R; Cai, T; Carini, M; Gavazzi, A; Geppetti, P; Giubilei, G; Gontero, P; Mondaini, N; Ungar, A, 2006)
"To perform a prospective, placebo-controlled study to examine the long-term efficacy of alfuzosin compared with placebo and standard therapy in patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), because alpha-blockers have been suggested for the treatment of CP/CPPS."5.10Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled, pilot study. ( Alas, P; Helström, PJ; Mehik, A; Nickel, JC; Sarpola, A, 2003)
"A double-blind, placebo-controlled study in 20 patients with 'prostatitis syndromes' and confirmed urodynamic abnormalities using the alpha 1-receptor-blocking compound alfuzosin is reported."5.07Research in 'prostatitis syndromes': the use of alfuzosin (a new alpha 1-receptor-blocking agent) in patients mainly presenting with micturition complaints of an irritative nature and confirmed urodynamic abnormalities. ( de Boo, T; de la Rosette, JJ; Debruyne, FM; Karthaus, HF; van Kerrebroeck, PE, 1992)
"Prostatitis is a common urologic diagnosis."2.43The management of chronic prostatitis in men with HIV. ( Lowe, FC; Santillo, VM, 2006)

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (9.09)18.2507
2000's9 (81.82)29.6817
2010's1 (9.09)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Nickel, JC4
Krieger, JN1
McNaughton-Collins, M1
Anderson, RU1
Pontari, M1
Shoskes, DA2
Litwin, MS1
Alexander, RB1
White, PC1
Berger, R1
Nadler, R1
O'Leary, M1
Liong, ML1
Zeitlin, S1
Chuai, S1
Landis, JR1
Kusek, JW1
Nyberg, LM1
Schaeffer, AJ1
Wagenlehner, FM1
Weidner, W1
Kattan, MW1
Mehik, A1
Alas, P1
Sarpola, A1
Helström, PJ1
Mondaini, N1
Giubilei, G1
Ungar, A1
Gontero, P1
Cai, T1
Gavazzi, A1
Bartoletti, R1
Geppetti, P2
Carini, M1
Santillo, VM1
Lowe, FC1
Magri, V2
Trinchieri, A2
Montanari, E1
Del Nero, A1
Mangiarotti, B1
Zirpoli, P1
de Eguileor, M1
Marras, E2
Ceriani, I2
Vral, A1
Perletti, G2
Nassini, R1
Materazzi, S1
Benemei, S1
de la Rosette, JJ1
Karthaus, HF1
van Kerrebroeck, PE1
de Boo, T1
Debruyne, FM1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Efficacy Study of Tamsulosin and Tolterodine Treatment of Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome and Lower Urinary Tract Symptoms[NCT00913315]30 participants (Anticipated)Interventional2009-08-31Not yet recruiting
A Randomized Clinical Trial to Evaluate the Efficacy and Safety of 10mg Alfuzosin in the Treatment of Chronic Prostatitis / Chronic Pelvic Pain Syndrome (CP/CPPS) in Recently-Diagnosed and/or Newly-Symptomatic Alpha-blocker Naïve Patients[NCT00103402]Phase 3272 participants (Actual)Interventional2005-02-28Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Hospital Anxiety and Depression Scale

For the Hospital Anxiety and Depression Scale, higher scores indicate greater anxiety and depression; range, 0 to 42. (NCT00103402)
Timeframe: Baseline and 12 weeks

Interventionunits on a scale (Mean)
Alfuzosin-2.6
Placebo-1.5

Change in International Index of Erectile Dysfunction (IIEF)

For the International Index of Erectile Function, higher scores indicate better sexual function; range, 0 to 75. (NCT00103402)
Timeframe: Baseline and 12 weeks

Interventionunits on a scale (Mean)
Alfuzosin0.5
Placebo-0.2

Change in Male Sexual Health Questionnaire

For the Male Sexual Health Questionnaire, higher scores indicate better function with respect to erection and ejaculation and greater satisfaction with sexual life; range, 0 to 40. (NCT00103402)
Timeframe: Baseline and 12 weeks

Interventionunits on a scale (Mean)
Alfuzosin1.7
Placebo0.6

Number of Participants With Decline in Total Score ≥4 for the NIH-CPSI Total Score From Baseline to 12 Weeks

For the National Institutes of Health Chronic Prostatitis Symptom Index (NIHCPSI) total score, higher scores indicate more severe symptoms and scores range from 0 to 43. The primary outcome was a decline of at least 4 from baseline to 12 weeks (NCT00103402)
Timeframe: Baseline and 12 weeks

InterventionParticipants (Count of Participants)
Alfuzosin68
Placebo66

Change in Medical Outcomes Study Short Form 12

For the Medical Outcomes Study Short Form Health Survey 12 (SF-12), higher scores indicate better quality of life. Score range for both the physical and mental component summaries is 0 to 100. (NCT00103402)
Timeframe: Baseline and 12 weeks

,
Interventionunits on a scale (Mean)
Physical componentMental component
Alfuzosin3.04.0
Placebo3.51.9

Change in Subscales of the McGill Pain Questionnaire

For the McGill Pain Questionnaire, higher scores indicate greater pain. Score ranges are as follows: total score, 0 to 45; sensory score, 0 to 33; affective score, 0 to 12. (NCT00103402)
Timeframe: Baseline and 12 weeks

,
Interventionunits on a scale (Mean)
Total scoreSensory scoreAffective score
Alfuzosin-3.4-2.5-1.0
Placebo-3.1-2.3-0.9

Change in Subscales of the NIH-CPSI

For the National Institutes of Health Chronic Prostatitis Symptom Index (NIHCPSI), higher scores indicate more severe symptoms (for the quality-of-life score, higher scores indicate a more negative effect). Score ranges are as follows: total score, 0 to 43; pain score, 0 to 21; urinary score, 0 to 10, quality-of-life score, 0 to 12; and average pain and urgency scores, 0 to 10. (NCT00103402)
Timeframe: Baseline and12 weeks

,
Interventionunits on a scale (Mean)
Total scorePain scoreUrinary scoreQuality-of-life score
Alfuzosin-7.1-3.3-1.2-1.2
Placebo-6.5-3.0-1.0-1.2

Reviews

3 reviews available for alfuzosin and Prostatitis

ArticleYear
The management of chronic prostatitis in men with HIV.
    Current urology reports, 2006, Volume: 7, Issue:4

    Topics: Adrenergic alpha-Antagonists; Algorithms; Antiretroviral Therapy, Highly Active; Chronic Disease; Co

2006
The concept of neurogenic inflammation.
    BJU international, 2008, Volume: 101 Suppl 3

    Topics: Adrenergic alpha-Antagonists; Animals; Calcium Channels; Humans; Male; Nerve Tissue Proteins; Neurog

2008
Role of alpha1-blockers in chronic prostatitis syndromes.
    BJU international, 2008, Volume: 101 Suppl 3

    Topics: Adrenergic alpha-Antagonists; Anti-Infective Agents; Bacterial Infections; Chronic Disease; Clinical

2008

Trials

4 trials available for alfuzosin and Prostatitis

ArticleYear
Alfuzosin and symptoms of chronic prostatitis-chronic pelvic pain syndrome.
    The New England journal of medicine, 2008, Dec-18, Volume: 359, Issue:25

    Topics: Adrenergic alpha-Antagonists; Adult; Aged; Chronic Disease; Humans; Male; Middle Aged; Pelvic Pain;

2008
Alfuzosin and symptoms of chronic prostatitis-chronic pelvic pain syndrome.
    The New England journal of medicine, 2008, Dec-18, Volume: 359, Issue:25

    Topics: Adrenergic alpha-Antagonists; Adult; Aged; Chronic Disease; Humans; Male; Middle Aged; Pelvic Pain;

2008
Alfuzosin and symptoms of chronic prostatitis-chronic pelvic pain syndrome.
    The New England journal of medicine, 2008, Dec-18, Volume: 359, Issue:25

    Topics: Adrenergic alpha-Antagonists; Adult; Aged; Chronic Disease; Humans; Male; Middle Aged; Pelvic Pain;

2008
Alfuzosin and symptoms of chronic prostatitis-chronic pelvic pain syndrome.
    The New England journal of medicine, 2008, Dec-18, Volume: 359, Issue:25

    Topics: Adrenergic alpha-Antagonists; Adult; Aged; Chronic Disease; Humans; Male; Middle Aged; Pelvic Pain;

2008
Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled, pilot study.
    Urology, 2003, Volume: 62, Issue:3

    Topics: Adrenergic alpha-Antagonists; Adult; Aged; Chronic Disease; Double-Blind Method; Humans; Male; Middl

2003
Alfuzosin (10 mg) does not affect blood pressure in young healthy men.
    European urology, 2006, Volume: 50, Issue:6

    Topics: Adrenergic alpha-Antagonists; Adult; Blood Pressure; Cross-Over Studies; Dose-Response Relationship,

2006
Research in 'prostatitis syndromes': the use of alfuzosin (a new alpha 1-receptor-blocking agent) in patients mainly presenting with micturition complaints of an irritative nature and confirmed urodynamic abnormalities.
    European urology, 1992, Volume: 22, Issue:3

    Topics: Adrenergic alpha-Antagonists; Adult; Double-Blind Method; Humans; Male; Middle Aged; Prostatitis; Qu

1992

Other Studies

4 other studies available for alfuzosin and Prostatitis

ArticleYear
Prostatitis: no benefit of alpha-blockers for chronic prostatitis.
    Nature reviews. Urology, 2009, Volume: 6, Issue:4

    Topics: Adrenergic alpha-Antagonists; Chronic Disease; Humans; Male; Prostatitis; Quinazolines; Randomized C

2009
Phenotypically directed multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome: a prospective study using UPOINT.
    Urology, 2010, Volume: 75, Issue:6

    Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Benzhydryl Compounds; Chronic Disease; Cohort

2010
Reduction of PSA values by combination pharmacological therapy in patients with chronic prostatitis: implications for prostate cancer detection.
    Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica, 2007, Volume: 79, Issue:2

    Topics: Adrenergic alpha-Antagonists; Adult; Aged; Algorithms; Androgen Antagonists; Anti-Bacterial Agents;

2007
Eradication of unusual pathogens by combination pharmacological therapy is paralleled by improvement of signs and symptoms of chronic prostatitis syndrome.
    Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica, 2007, Volume: 79, Issue:2

    Topics: Adrenergic alpha-Antagonists; Adult; Androgen Antagonists; Anti-Bacterial Agents; Anti-Infective Age

2007